• Mashup Score: 50
    Southern Tick-Associated Rash Illness | NEJM - 11 hour(s) ago

    A 65-year-old man presented with 1-day history of a rash with a bull’s-eye appearance on his left hip. One week earlier, he had removed a tick from his hip after doing yard work near the woods by h…

    Source: www.nejm.org
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of NEJM
      NEJM

      A 65-year-old man presented with a 1-day history of a rash with a bull’s-eye appearance on his left hip. One week earlier, he had removed a tick from his hip after doing yard work near the woods by his home in Tennessee. Read the full case details: https://t.co/23f107tpKx This https://t.co/0xKV1SXyTz

  • Mashup Score: 19
    Climate Change and Human Health — A Research Agenda for Action | NEJM - 15 hour(s) ago

    A new report from the National Academy of Medicine proposes a research agenda to address climate-related health risks and data gaps, emphasizing equity, innovation, and interdisciplinary collaboration.

    Source: www.nejm.org
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of NEJM
      NEJM

      A new report from the National Academy of Medicine (@theNAMedicine) proposes a research agenda to address climate-related health risks and data gaps, emphasizing equity, innovation, and interdisciplinary collaboration. Read the full report: https://t.co/6FWsCs00wB https://t.co/8MOnzQkmdL

  • Mashup Score: 23
    Long-Term Effects of Atidarsagene Autotemcel for Metachromatic Leukodystrophy | NEJM - 16 hour(s) ago

    Metachromatic leukodystrophy (MLD) is an ultrarare, severe lysosomal storage disorder caused by a deficiency of arylsulfatase A (ARSA). We treated patients who had MLD with atidarsagene autotemcel …

    Source: www.nejm.org
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of NEJM
      NEJM

      A comparison of clinical outcomes in 39 patients treated with atidarsagene autotemcel, a hematopoietic stem-cell–based gene therapy, with those of untreated patients showed a strong treatment effect over the long term. Full study results: https://t.co/70p4RMWDpg https://t.co/j6bDPOTJwG

  • Mashup Score: 88
    Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis | NEJM - 19 hour(s) ago

    In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP…

    Source: www.nejm.org
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of NEJM
      NEJM

      In the ASPEN phase 3 trial involving patients with noncystic fibrosis bronchiectasis, the rate of pulmonary exacerbations over a 52-week period was lower with brensocatib (10 mg or 25 mg per day) than with placebo. Full trial results: https://t.co/o31wPc2oNR Editorial: https://t.co/8JP33VW782

  • Mashup Score: 15
    Fidanacogene Elaparvovec for Hemophilia B — A Multiyear Follow-up Study | NEJM - 21 hour(s) ago

    Treatment with fidanacogene elaparvovec, a recombinant adeno-associated virus (AAV) vector developed for the treatment of hemophilia B, led to sustained expression of the high-activity factor IX va…

    Source: www.nejm.org
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of NEJM
      NEJM

      In a long-term follow-up study, a single dose of fidanacogene elaparvovec was found to lead to sustained factor IX expression in liver cells and dramatically lowered annualized bleeding rates in 14 patients with hemophilia B. Full study results: https://t.co/1O6jGeYExb https://t.co/p4si5TtEON

Load More